Structure-based optimization of CDK2 inhibitors

• Autorzy: Schafer M , Briem H. , Brumby T. , Eberspacher U. , Grimm M. , Haberey M. , Hess-Stumpp H. , Jautelat R. , Kruger M. , Lucking U. , Prien O. , Reichel A. , Siemeister G. , Steinmeyer A.
• Języki publikacji: EN

Słowa kluczowe

EN

cell cycle; anticancer drug; antiproliferative agent; enzyme; cyclin-dependent protein kinase; inhibitor

• Wydawca: -
• Czasopismo: Cellular and Molecular Biology Letters
• Rocznik: 2003
• Tom: 08
• Numer: 2A
• Opis fizyczny: p.562-563

Twórcy

autor

Schafer M

autor

Briem H.

autor

Brumby T.

autor

Eberspacher U.

autor

Grimm M.

autor

Haberey M.

autor

Hess-Stumpp H.

autor

Jautelat R.

autor

Kruger M.

autor

Lucking U.

autor

Prien O.

autor

Reichel A.

autor

Siemeister G.

autor

Steinmeyer A.

Bibliografia

• 1. Gray, N., Detivaud, L., Doerig, C. and Meijer, L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr, Med. Chem. 6 (1999) 859-875.
• 2. Fischer, P.M. and Lane D.P. Inhibitors of cyclin-dependent kinases as anticancer therapeutics. Curr. Med. Chem. 7 (2000) 1213-1245.
• 3. Toogood, P.L. Cyclin-dependent kinase inhibitors for treating cancer, Med. Res. Rev. 21 (2001) 487-498.
• 4. Endicott, J.A., Noble, M.E. and Tucker, J.A. Cyclin-dependent kinases: Inhibition and substrate recognition. Curr. Opin. Struct. Biol. 9 (1999) 738-744.
• 5. Hardcastle, I.R., Golding, B.T. and Griffin, RJ. Designing inhibitors of cyclin-dependent kinases. Annu. Rev. Pharmacol. Toxicol. 42 (2002) 325-348.
• 6. Scapin, G. Structural biology in drug design: selective protein kinase inhibitors. Drug Discov. Today 7 (2002) 601-611.